Syneos Health announced the promotions of two senior internal leaders – Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice President, Medical Affairs.
Unvaccinated people infected with the Omicron variant are unlikely to develop immune responses that will protect them against other variants of the coronavirus, a new study suggests. Additionally, the average number of global deaths from COVID-19 were 6 percent higher on weekends compared to weekdays throughout the pandemic, according to statistics reported to the World Health Organization between March 2020 and March 2022.
A new study found that disulfiram, a drug used to treat chronic alcoholism, can safely reduce anxiety levels in rodents.
Magenta Therapeutics is reducing the company’s workforce by 14 percent in a revised operating plan to prioritize research and development.
A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
Mallinckrodt plc announced the publication of findings from a retrospective chart review study assessing the real-world use and outcomes of INOmax (nitric oxide) gas, for inhalation therapy in hospitalized patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome (ARDS), a disorder in which fluid leaks into the lungs, making breathing difficult or impossible. The results of the study were published in the peer-reviewed journal Drugs in Context.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.
The U.S. Food and Drug Administration placed a partial clinical hold on the TakeAim lymphoma study while the biotech company Curis provides further data to better understand safety and efficacy questions.
Shares of Veru Inc. soared nearly 200 percent after the Florida-based company announced its Phase III COVID-19 antiviral treatment was halted early based on positive efficacy following an Independent Data Monitoring Committee’s recommendation.
Gilead Sciences Inc. said on April 11 the U.S. Food and Drug Administration had lifted the partial clinical hold placed on the company’s trials testing a blood cancer drug combination.
